Aequus Pharmaceuticals has a pipeline of commercial and near-commercial-stage products that have been brought in through an acquisition or license to be marketed and sold in Canada. This commercial pipeline consists of specialty products and forms the base for niche therapeutic franchises we plan to expand into it. We will continue to in-license and/or acquire high quality, differentiated products within these focused therapeutic areas. To learn more about our partnering strategy, click here.

Aequus' development-stage products are strategically focused on addressing the need for improved medication adherence through enhanced delivery systems. Our lead programs are expected to follow a 505(b)2 pathway to approval in the United States. We intend to commercialize these products directly in Canada using our established CNS sales force and through partners in other territories.

*Currently marketed in the United States by Supernus Pharmaceuticals. Aequus expects to file for regulatory submission in Canada in 2017.
1 Aequus carries out the Canadian promotional activity for tacrolimus IR and Vistitan™ 
TM: Trademark owned or used under license by Sandoz Canada Inc. 
TDS = Transdermal Delivery System
Tacrolimus IR (tacrolimus immediate release capsules) is indicated for the prophylaxis of organ rejection in patients receiving allogenic liver, kidney or heart transplants and for the treatment of refractory rejection in patients receiving allogenic liver, kidney or heart transplants. For more information, please refer to the product monograph
Vistitan™ (bimatoprost ophthalmic solution 0.03% w/v) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. For more information, please refer to the product monograph